Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 13/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | DHODH | Q02127 | 2/20 | 0.33 |
| ▸ | JAK2 | O60674 | 2/20 | 0.32 |
| ▸ | JAK1 | P23458 | 2/20 | 0.32 |
| ▸ | JAK3 | P52333 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20697304 | 0.83 | TYK2 (0.40) | TYK2DHODH | |
| SCHEMBL20689185 | 0.83 | TYK2 (0.40) | TYK2DHODH | |
| SCHEMBL21948036 | 0.82 | TYK2 (0.44) | TYK2TMEM97HTR2BDHODH | |
| SCHEMBL21947985 | 0.82 | TYK2 (0.46) | TYK2TRPA1 | |
| SCHEMBL21947986 | 0.79 | TYK2 (0.46) | TYK2TRPA1 | |
| SCHEMBL15803819 | 0.78 | IL4I1 (0.39) | TYK2TMEM97HTR2BHTR2ASIGMAR1 | |
| SCHEMBL16812515 | 0.78 | IL4I1 (0.39) | TYK2TMEM97HTR2BHTR2ASIGMAR1 | |
| SCHEMBL16794604 | 0.77 | GLA (0.40) | TYK2TMEM97HTR2BDHODH | |
| SCHEMBL27354759 | 0.75 | DHODH (0.35) | TYK2DHODH | |
| SCHEMBL16794667 | 0.75 | DHODH (0.40) | TYK2TMEM97HTR2BDHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200131201-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-04-30 | — | — | US | disclosed |
| WO-2020081508-A1 | TYK2 INHIBITORS AND USES THEREOF | NIMBUS LAKSHMI, INC. (US) | 2020-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131201-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | TYK2 1/4885TRPA1 4793/4885TMEM97 4130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.